Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

In-Vitro Transcription Templates Market by Disease Type (Cancer, Infectious Disease, Lifestyle Disease, Genetic Disease, Others), by Treatment Type (Vaccine, Therapeutic) and by End User (Pharmaceutical Companies, Academic Institutes, Research Institutes, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A13362

Pages: NA

Charts: NA

Tables: NA

In-vitro transcription is a procedure in which bacteriophage DNA-dependent RNA polymerase is used in the synthesis of RNA of any sequence from DNA templates. Moreover, this is a process of copying segment of DNA into RNA. Segments of DNA transcribed into RNA molecules that can encode proteins are said to produce messenger RNA (mRNA). Other segments of DNA are copied into RNA molecules called as non-coding RNA (ncRNA). Synthesized RNA transcripts are further used for analysis of cellular RNA functionality in methods such as spilicing, RNA processing, intracellular transport, viral infectivity, and translation

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

There has been an increase in the demand for medical supplies to take care of infected population. Respiratory support devices such as atomizers, life-support machines, oxygen generators, and monitors are among the majorly used medical devices in primary clinical treatment. Moreover, COVID-19 has led to a huge surge in demand for medical supplies such as personal protective equipment including masks, gloves, and protective eyeglasses. There is an increase in the need for medical supplies, both from healthcare professionals and civil population for precautionary measures, owing to the rise in number of COVID-19 cases worldwide. Manufacturers of these products have a chance to capitalize this increased demand for medical supplies to ensure adequate and continuous supply of personal protective equipment in the market. Therefore, COVID-19 is expected to have a significant impact on the in-vitro transcription templates market.

Top Impacting Factors

  • Rise in cases of chronic diseases such as cancer and infectious diseases across the globe, surge in demand for early detection & diagnosis of diseases, increase in prevalence of rare genetic disorders, rise in demand for targeted drug therapy, and outbreak of infectious diseases globally are the key factors that drive the growth of the market.
  • In addition, increase in advancement in biotechnology, rise in massive investment in pharmaceutical sector by private & government funding, ongoing research on gene editing & drug formation by research institutes, surge in technological advancement to launch novel transcription methods, rise in adoption of transcription methods for customized medication, and strategic development by key market players are expected to boost the growth of the market.
  • However, high cost associated with instruments & maintenance of transcription templetes hinder the growth of the market.
  • Contrarily, rise in focus on R&D activities for cost effective treatment are expected to offer lucrative opportunities for the expansion of the market.

Market Trends

Rise in Usage of In-Vitro Transcription Templates

As per the data of Moderna 2020, announced approval for emergency use of RNA vaccine for treatment of COVID-19. Moreover, this RNA vaccine was found to be 95% effective. In addition, surge in cases of viral infection cases, surge in expenses on healthcare sectors, joint venture, collaboration & mergers between local market players to increase development, and adaptation of advance healthcare systems are expected to boost the growth of the market.

Key Benefits of the Report

  • This study presents the analytical depiction of in-vitro transcription templates market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the In-Vitro Transcription Templates Market Report    

  • Which are the leading players active in the in-vitro transcription templates market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "in-vitro transcription templates"?
  • What is "in-vitro transcription templates" market prediction in the future?
  • Who are the leading global players in the "in-vitro transcription templates" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "in-vitro transcription templates" market report?

 Key Market Segments

  • By Disease Type
    • Cancer
    • Infectious Disease
    • Lifestyle Disease
    • Genetic Disease
    • Others
  • By Treatment Type
    • Vaccine
    • Therapeutic
  • By End User
    • Pharmaceutical Companies
    • Academic Institutes
    • Research Institutes
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • New England Biolabs
  • Cytiva (Danaher)
  • Lucigen
  • Agilent Technologies
  • Enzynomics co Ltd.
  • Bio-Synthesis Inc.
  • Thermo Fisher Scientific Inc.
  • Promega Corporation
  • Enzo Life Sciences, Inc.
  • Takara Bio USA (a Takara Bio Company)

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: IN-VITRO TRANSCRIPTION TEMPLATES MARKET, BY DISEASE TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Disease Type

    • 4.2. Cancer

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Infectious Disease

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Lifestyle Disease

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Genetic Disease

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: IN-VITRO TRANSCRIPTION TEMPLATES MARKET, BY TREATMENT TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Treatment Type

    • 5.2. Vaccine

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Therapeutic

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: IN-VITRO TRANSCRIPTION TEMPLATES MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Pharmaceutical Companies

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Academic Institutes

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Research Institutes

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Others

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: IN-VITRO TRANSCRIPTION TEMPLATES MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Disease Type

      • 7.2.3. Market Size and Forecast, By Treatment Type

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. In-vitro Transcription Templates Market

        • 7.2.6.1. Market Size and Forecast, By Disease Type
        • 7.2.6.2. Market Size and Forecast, By Treatment Type
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada In-vitro Transcription Templates Market

        • 7.2.7.1. Market Size and Forecast, By Disease Type
        • 7.2.7.2. Market Size and Forecast, By Treatment Type
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico In-vitro Transcription Templates Market

        • 7.2.8.1. Market Size and Forecast, By Disease Type
        • 7.2.8.2. Market Size and Forecast, By Treatment Type
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Disease Type

      • 7.3.3. Market Size and Forecast, By Treatment Type

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France In-vitro Transcription Templates Market

        • 7.3.6.1. Market Size and Forecast, By Disease Type
        • 7.3.6.2. Market Size and Forecast, By Treatment Type
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany In-vitro Transcription Templates Market

        • 7.3.7.1. Market Size and Forecast, By Disease Type
        • 7.3.7.2. Market Size and Forecast, By Treatment Type
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy In-vitro Transcription Templates Market

        • 7.3.8.1. Market Size and Forecast, By Disease Type
        • 7.3.8.2. Market Size and Forecast, By Treatment Type
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain In-vitro Transcription Templates Market

        • 7.3.9.1. Market Size and Forecast, By Disease Type
        • 7.3.9.2. Market Size and Forecast, By Treatment Type
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK In-vitro Transcription Templates Market

        • 7.3.10.1. Market Size and Forecast, By Disease Type
        • 7.3.10.2. Market Size and Forecast, By Treatment Type
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia In-vitro Transcription Templates Market

        • 7.3.11.1. Market Size and Forecast, By Disease Type
        • 7.3.11.2. Market Size and Forecast, By Treatment Type
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe In-vitro Transcription Templates Market

        • 7.3.12.1. Market Size and Forecast, By Disease Type
        • 7.3.12.2. Market Size and Forecast, By Treatment Type
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Disease Type

      • 7.4.3. Market Size and Forecast, By Treatment Type

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China In-vitro Transcription Templates Market

        • 7.4.6.1. Market Size and Forecast, By Disease Type
        • 7.4.6.2. Market Size and Forecast, By Treatment Type
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan In-vitro Transcription Templates Market

        • 7.4.7.1. Market Size and Forecast, By Disease Type
        • 7.4.7.2. Market Size and Forecast, By Treatment Type
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India In-vitro Transcription Templates Market

        • 7.4.8.1. Market Size and Forecast, By Disease Type
        • 7.4.8.2. Market Size and Forecast, By Treatment Type
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea In-vitro Transcription Templates Market

        • 7.4.9.1. Market Size and Forecast, By Disease Type
        • 7.4.9.2. Market Size and Forecast, By Treatment Type
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia In-vitro Transcription Templates Market

        • 7.4.10.1. Market Size and Forecast, By Disease Type
        • 7.4.10.2. Market Size and Forecast, By Treatment Type
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand In-vitro Transcription Templates Market

        • 7.4.11.1. Market Size and Forecast, By Disease Type
        • 7.4.11.2. Market Size and Forecast, By Treatment Type
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia In-vitro Transcription Templates Market

        • 7.4.12.1. Market Size and Forecast, By Disease Type
        • 7.4.12.2. Market Size and Forecast, By Treatment Type
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia In-vitro Transcription Templates Market

        • 7.4.13.1. Market Size and Forecast, By Disease Type
        • 7.4.13.2. Market Size and Forecast, By Treatment Type
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific In-vitro Transcription Templates Market

        • 7.4.14.1. Market Size and Forecast, By Disease Type
        • 7.4.14.2. Market Size and Forecast, By Treatment Type
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Disease Type

      • 7.5.3. Market Size and Forecast, By Treatment Type

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil In-vitro Transcription Templates Market

        • 7.5.6.1. Market Size and Forecast, By Disease Type
        • 7.5.6.2. Market Size and Forecast, By Treatment Type
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa In-vitro Transcription Templates Market

        • 7.5.7.1. Market Size and Forecast, By Disease Type
        • 7.5.7.2. Market Size and Forecast, By Treatment Type
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia In-vitro Transcription Templates Market

        • 7.5.8.1. Market Size and Forecast, By Disease Type
        • 7.5.8.2. Market Size and Forecast, By Treatment Type
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE In-vitro Transcription Templates Market

        • 7.5.9.1. Market Size and Forecast, By Disease Type
        • 7.5.9.2. Market Size and Forecast, By Treatment Type
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina In-vitro Transcription Templates Market

        • 7.5.10.1. Market Size and Forecast, By Disease Type
        • 7.5.10.2. Market Size and Forecast, By Treatment Type
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA In-vitro Transcription Templates Market

        • 7.5.11.1. Market Size and Forecast, By Disease Type
        • 7.5.11.2. Market Size and Forecast, By Treatment Type
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Lucigen

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Promega Corporation

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Enzynomics Co Ltd.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Enzo Life Sciences, Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Takara Bio USA (a Takara Bio Company)

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Bio-Synthesis Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Agilent Technologies

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Thermo Fisher Scientific Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Cytiva (Danaher)

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. New England Biolabs

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR INFECTIOUS DISEASE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR LIFESTYLE DISEASE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR GENETIC DISEASE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR VACCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR THERAPEUTIC, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA IN-VITRO TRANSCRIPTION TEMPLATES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 20. U.S. IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 21. U.S. IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 22. U.S. IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 23. CANADA IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 24. CANADA IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 25. CANADA IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE IN-VITRO TRANSCRIPTION TEMPLATES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 39. ITALY IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 40. ITALY IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 41. ITALY IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. UK IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 46. UK IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 47. UK IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC IN-VITRO TRANSCRIPTION TEMPLATES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 58. CHINA IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 59. CHINA IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 60. CHINA IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. INDIA IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 65. INDIA IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 66. INDIA IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA IN-VITRO TRANSCRIPTION TEMPLATES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 98. UAE IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 99. UAE IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 100. UAE IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA IN-VITRO TRANSCRIPTION TEMPLATES, BY DISEASE TYPE, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA IN-VITRO TRANSCRIPTION TEMPLATES, BY TREATMENT TYPE, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA IN-VITRO TRANSCRIPTION TEMPLATES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 107. LUCIGEN: KEY EXECUTIVES
  • TABLE 108. LUCIGEN: COMPANY SNAPSHOT
  • TABLE 109. LUCIGEN: OPERATING SEGMENTS
  • TABLE 110. LUCIGEN: PRODUCT PORTFOLIO
  • TABLE 111. LUCIGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. PROMEGA CORPORATION: KEY EXECUTIVES
  • TABLE 113. PROMEGA CORPORATION: COMPANY SNAPSHOT
  • TABLE 114. PROMEGA CORPORATION: OPERATING SEGMENTS
  • TABLE 115. PROMEGA CORPORATION: PRODUCT PORTFOLIO
  • TABLE 116. PROMEGA CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. ENZYNOMICS CO LTD.: KEY EXECUTIVES
  • TABLE 118. ENZYNOMICS CO LTD.: COMPANY SNAPSHOT
  • TABLE 119. ENZYNOMICS CO LTD.: OPERATING SEGMENTS
  • TABLE 120. ENZYNOMICS CO LTD.: PRODUCT PORTFOLIO
  • TABLE 121. ENZYNOMICS CO LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. ENZO LIFE SCIENCES, INC.: KEY EXECUTIVES
  • TABLE 123. ENZO LIFE SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 124. ENZO LIFE SCIENCES, INC.: OPERATING SEGMENTS
  • TABLE 125. ENZO LIFE SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 126. ENZO LIFE SCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. TAKARA BIO USA (A TAKARA BIO COMPANY): KEY EXECUTIVES
  • TABLE 128. TAKARA BIO USA (A TAKARA BIO COMPANY): COMPANY SNAPSHOT
  • TABLE 129. TAKARA BIO USA (A TAKARA BIO COMPANY): OPERATING SEGMENTS
  • TABLE 130. TAKARA BIO USA (A TAKARA BIO COMPANY): PRODUCT PORTFOLIO
  • TABLE 131. TAKARA BIO USA (A TAKARA BIO COMPANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. BIO-SYNTHESIS INC.: KEY EXECUTIVES
  • TABLE 133. BIO-SYNTHESIS INC.: COMPANY SNAPSHOT
  • TABLE 134. BIO-SYNTHESIS INC.: OPERATING SEGMENTS
  • TABLE 135. BIO-SYNTHESIS INC.: PRODUCT PORTFOLIO
  • TABLE 136. BIO-SYNTHESIS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. AGILENT TECHNOLOGIES: KEY EXECUTIVES
  • TABLE 138. AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 139. AGILENT TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 140. AGILENT TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 141. AGILENT TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 143. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 144. THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 145. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 146. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. CYTIVA (DANAHER): KEY EXECUTIVES
  • TABLE 148. CYTIVA (DANAHER): COMPANY SNAPSHOT
  • TABLE 149. CYTIVA (DANAHER): OPERATING SEGMENTS
  • TABLE 150. CYTIVA (DANAHER): PRODUCT PORTFOLIO
  • TABLE 151. CYTIVA (DANAHER): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. NEW ENGLAND BIOLABS: KEY EXECUTIVES
  • TABLE 153. NEW ENGLAND BIOLABS: COMPANY SNAPSHOT
  • TABLE 154. NEW ENGLAND BIOLABS: OPERATING SEGMENTS
  • TABLE 155. NEW ENGLAND BIOLABS: PRODUCT PORTFOLIO
  • TABLE 156. NEW ENGLAND BIOLABS: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL IN-VITRO TRANSCRIPTION TEMPLATES MARKET
  • FIGURE 3. SEGMENTATION IN-VITRO TRANSCRIPTION TEMPLATES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN IN-VITRO TRANSCRIPTION TEMPLATES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIN-VITRO TRANSCRIPTION TEMPLATES MARKET
  • FIGURE 11. IN-VITRO TRANSCRIPTION TEMPLATES MARKET SEGMENTATION, BY BY DISEASE TYPE
  • FIGURE 12. IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR INFECTIOUS DISEASE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR LIFESTYLE DISEASE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR GENETIC DISEASE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. IN-VITRO TRANSCRIPTION TEMPLATES MARKET SEGMENTATION, BY BY TREATMENT TYPE
  • FIGURE 18. IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR VACCINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR THERAPEUTIC, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. IN-VITRO TRANSCRIPTION TEMPLATES MARKET SEGMENTATION, BY BY END USER
  • FIGURE 21. IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. IN-VITRO TRANSCRIPTION TEMPLATES MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: IN-VITRO TRANSCRIPTION TEMPLATES MARKET
  • FIGURE 31. TOP PLAYER POSITIONING, 2024
  • FIGURE 32. LUCIGEN: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. LUCIGEN: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. LUCIGEN: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. PROMEGA CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. PROMEGA CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. PROMEGA CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. ENZYNOMICS CO LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. ENZYNOMICS CO LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. ENZYNOMICS CO LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. ENZO LIFE SCIENCES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. ENZO LIFE SCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. ENZO LIFE SCIENCES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. TAKARA BIO USA (A TAKARA BIO COMPANY): NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. TAKARA BIO USA (A TAKARA BIO COMPANY): REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. TAKARA BIO USA (A TAKARA BIO COMPANY): REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. BIO-SYNTHESIS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. BIO-SYNTHESIS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. BIO-SYNTHESIS INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. AGILENT TECHNOLOGIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. AGILENT TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. AGILENT TECHNOLOGIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. THERMO FISHER SCIENTIFIC INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. CYTIVA (DANAHER): NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. CYTIVA (DANAHER): REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. CYTIVA (DANAHER): REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. NEW ENGLAND BIOLABS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. NEW ENGLAND BIOLABS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. NEW ENGLAND BIOLABS: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
In-Vitro Transcription Templates Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved